Skip to main content
. Author manuscript; available in PMC: 2023 Jan 14.
Published in final edited form as: Br J Haematol. 2022 Aug 27;200(2):137–149. doi: 10.1111/bjh.18418

Fig. 1. Resistance-Relevant mutations and signaling pathways in CLL, MCL and DLBCL.

Fig. 1

Key components of the signaling pathways including BCR, PI3K-AKT, MYD88/CD79, canonical NFκB and alternative NFκB are depicted. Mutated genes along these pathways associated with BTKi resistance are highlighted in yellow. Also see Table 4 for their relationship with the disease and resistance setting. Positive interactions are indicated by arrows, indirect interactions by dashed arrows, and inhibitory interactions by T-bars. The graph was generated with BioRender.